Aclidinium Bromide News
Aclidinium Bromide currently has 0 news articles, with 20 predicted indications.
This page combines the AI-predicted indications for Aclidinium Bromide with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Original indication: Bretaris Genuair is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
- Evidence level: L5
- Predicted indications (20):
- open-angle glaucoma (89.4%)
- primary hereditary glaucoma (89.0%)
- migraine disorder (86.2%)
- migraine with brainstem aura (85.4%)
- irritable bowel syndrome (84.6%)
- headache disorder (83.5%)
- trigeminal autonomic cephalalgia (82.7%)
- glaucoma 1, open angle (79.6%)
- gastroduodenitis (79.5%)
- dermatitis (79.3%)
- obsolete rare pulmonary disease (79.1%)
- peptic ulcer disease (78.5%)
- dysthymic disorder (78.0%)
- acrodermatitis chronica atrophicans (77.6%)
- common cold (77.2%)
- neonatal dermatomyositis (76.6%)
- hydroa vacciniforme, familial (76.0%)
- atrophoderma vermiculata (75.6%)
- secondary interstitial lung disease specific to childhood associated with a connective tissue disease (75.6%)
- amyopathic dermatomyositis (75.3%)
Related News (0)
No related news yet. When news mentions this drug, it will be collected and shown here automatically.
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.